Abstract
Some studies have suggested that a significant fraction of non-Hodgkin's lymphomas (NHL) do not express pRB protein, possibly due to deletions of RB1. We examined RB1/centromere 17 copy number by fluorescent in situ hybridisation, and pRB expression/phosphorylation by immunohistochemistry (IHC) and immunoblotting (IB) in 66 cases of B cell NHL. Thirteen cases had lost one RB1 copy relative to centromere 17 copy number and total DNA content. Case 458/88 had no RB1 copies. pRB levels were heterogeneous as assessed by IB (0.04–1.12 relative units), but all tumours, except for case 458/88, expressed pRB localised to the nucleus in >75% of the tumour cells by IHC. The fraction of phosphorylated pRB was correlated with pRB expression (r2 = 0.56, P < 0.001). The 14 cases with loss of RB1 had lower pRB expression (median 0.25) than those without (median 0.48, P < 0.001), but a correlation with S phase fraction (r2 = 0.43, P < 0.001; previously published data for tumour-specific S phase and apoptotic fractions) indicated that the variation in pRB expression was due to differences in proliferative activity. Furthermore, the regression lines for pRB expression vs S phase fraction were not different for the cases with or without loss of one RB1 copy (P = 0.5). Cases 154/88 (one RB1 copy) and 258/88 (two RB1 copies), in addition to case 458/88, had low expression of (hypophosphorylated) pRB (0.04, 0.08 and 0.04), despite their high S phase fractions (21%, 17% and 21%). There was no association between pRB expression/RB1 copy number and apoptotic fraction. Neither pRB expression nor loss of RB1 had prognostic value, but cases 154/88, 258/88, and 458/88 had short survival times (5, 3 and 46 months, respectively) compared to the others (median survival: 44 months, P = 0.03). It is suggested that pRB expression and function are normal in 63 of 66 NHL cases, including 12 of 13 lymphomas with loss of one RB1 allele.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Foon KA, Todd RF . Immunologic classification of leukemia and lymphoma Blood 1986 68: 1–31
Rabbitts TH . Chromosomal translocations in human cancer Nature 1994 372: 143–149
Knutsen T . Cytogenetic changes in the progression of Lymphoma Leuk Lymphoma 1998 31: 1–19
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P . Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 2000 343: 1910–1917
Peterson L, Lindquist LL, Church S, Kay NE . Frequent clonal abnormalities of chromosome band 13q14 in B-cell chronic lymphocytic leukemia: multiple clones, subclones, and nonclonal alterations in 82 Midwestern patients Genes Chromos Cancer 1992 4: 273–280
Wada M, Okamura T, Okada M, Teramura M, Masuda M, Motoji T, Mizoguchi H . Frequent chromosome arm 13q deletion in aggressive non-Hodgkin's lymphoma Leukemia 1999 13: 792–798
Liu Y, Hermanson M, Grander D, Merup M, Wu X, Heyman M, Rasool O, Juliusson G, Gahrton G, Detlofsson R, Nikiforova N, Buys C, Söderhäll S, Yankovsky N, Zabarovsky E, Einhorn S . 13q deletions in lymphoid malignancies Blood 1995 86: 1911–1915
Liu Y, Szekely L, Grander D, Söderhäll S, Juliusson G, Gahrton G, Linder S, Einhorn S . Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB-1 gene: evidence for a role of an adjacent locus Proc Natl Acad Sci USA 1993 90: 8697–8701
Rosenwald A, Ott G, Krumdiek AK, Dreyling MH, Katzenberger T, Kalla J, Roth S, Ott MM, Muller-Hermelink HK . A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral T-cell lymphomas? Genes Chromos Cancer 1999 26: 210–214
Stokke T, Erikstein BK, Smhammer L eds Boye E, Steen HB . The retinoblastoma gene product is bound in the nucleus in early G1 phase Exp Cell Res 1993 204: 147–155
Szekely L, Pokrovskaja K, Jiang W-Q, Selivanova G, Löwbeer M, Ringertz N, Wiman KG, Klein G . Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their Rb, p53 and EBNA-5 expression patterns Oncogene 1995 10: 1869–1874
Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, Delecluse HJ, Rottenberger C, Bornkamm GW, Hammerschmidt W . B-cell proliferation and induction of early G1-regulating proteins by Epstein–Barr virus mutants conditional for EBNA2 EMBO J 1995 14: 88–96
Hollyoake M, Sthler A, Farrell P, Gordon J, Sinclair A . The normal cell cycle activation program is exploited during the infection of quiescent B-lymphocytes by Epstein–Barr virus Cancer Res 1995 55: 4784–4787
Lipinski MM, Jacks T . The retinoblastoma gene family in differentiation and development Oncogene 1999 18: 7873–7882
Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K, Lu X . E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction Genes Dev 1997 11: 1840–1852
Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH . Induction of DNA synthesis and apoptosis are separable functions of E2F1 Genes Dev 1997 11: 1853–1863
Sherr CJ . Cancer cell cycles Science 1996 274: 1672–1677
Nobori T, Mlura K, Wu DJ, Lois A, Takabayashi K, Carson DA . Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers Nature 1994 368: 753–756
Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Kunihiko T, Hirosawa S, Kamada N, Kobayashi Y, Takemoto Y, Kitani T, Toyama K, Ohtake S, Yazaki Y, Ueda R, Hirai H . Inactivation of multiple tumour suppressor genes involved in negative regulation of the cell cycle. MTS/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies Blood 1996 87: 4949–4958
Wang JYJ, Knudsen ES, Welch PJ . The retinoblastoma suppressor protein Adv Cancer Res 1994 64: 25–85
Horowitz JM, Park S-H, Bogenmann E, Cheng J-C, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA . Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumour cells Proc Natl Acad Sci USA 1990 87: 2775–2779
Martinez JC, Piris MA, Sanchezbeato M, Villuendas R, Orradre JL, Algara P, Sanchezverde L, Martinez P . Retinoblastoma (Rb) gene-product expression in lymphomas – correlation with Ki67 growth fraction J Pathol 1993 169: 405–412
Weide R, Tiemann M, Pflÿger K-H, Köppler H, Parvizl B, Wacker H-H, Kreipe H-H, Havemann K, Parwaresch MR . Altered expression of the retinoblastoma gene product in human high-grade non-Hodgkin's lymphomas Leukemia 1994 8: 97–101
Kornblau SM, Chen N, del Giglio A, O'Brien S, Deisseroth AB . Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia Cancer Res 1994 54: 242–246
Møller MB, Kania PW, Ino Y, Gerdes A-M, Nielsen O, Louis DN, Skjødt K . Frequent disruption of the RB-1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A Leukemia 2000 14: 898–904
Kiviniemi M, Sauroja I, Rajamäki A, Punnonen K, Söderström KO, Salminen E . Cell cycle regulators p27 and pRb in lymphomas – correlation with histology and proliferative activity Br J Cancer 2000 83: 1161–1167
Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, Sanchez-Beato M, Soler F, Perez-Losada A, Nayach I, Mallofre C, Piris MA, Montserrat E, Cardesa A . Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas Am J Pathol 1996 148: 1591–1600
Nguyen PL, Zukerberg LR, Benedict WF, Harris NL . Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma Am J Clin Pathol 1996 105: 538–543
Geradts J, Andriko JW, Abbondanzo SL . Loss of tumour suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas Am J Clin Pathol 1998 109: 669–674
Grierson AJ, Hodgkins MA, Hancock BW, Goepel JR, Royds J, Goyns MH . Investigation of the RB-1 tumour suppressor gene in a United Kingdom series of non-Hodgkin's lymphomas Leuk Lymphoma 1996 23: 353–363
Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R . Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma Blood 1993 81: 166–176
Scheffner M, Munger K, Byrne JC, Howley PM . The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines Proc Natl Acad Sci USA 1991 88: 5523–5527
Horowitz JM, Yandell DW, Park S-H, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA, Dryja TP . Point mutational inactivation of the retinoblastoma antioncogene Science 1989 243: 937–940
Mittnacht S, Weinberg RA . G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment Cell 1991 65: 381–393
Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR . The E2F transcription factor is a cellular target for the RB protein Cell 1991 65: 1053–1061
Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, Hiddelmann W, Döhner H . Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma Cancer Res 1997 57: 4608–4614
Galteland E, Holte H, Stokke T . c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridisation Cytometry 1999 38: 53–60
Stokke T, Galteland E, Holte H, Smhammer L eds Suo Z, Smeland EB, Børresen-Dale AL, Deangelis P, Steen HB . Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell non-Hodgkin's lymphoma Int J Cancer 2000 89: 313–324
Stokke T, Holte H, Smhammer L eds Smeland EB, Kaalhus O, Steen HB . Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas Br J Cancer 1998 77: 1832–1838
Holte H, Suo Z, Smeland EB, Kvaløy S, Langholm R, Stokke T . The prognostic value of lymphoma-specific S-phase compared with other cell proliferation markers Acta Oncologica 1999 38: 495–503
DeAngelis P, Stokke T, Smhammer L eds Lothe RA, Lehne G, Chen Y, Clausen OP . P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo Br J Cancer 1995 72: 307–311
Lømo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK . Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B-lymphocytes Cancer Res 1996 56: 40–43
Kraggerud SM, Jacobsen KD, Berner Å, Stokke T, Holm R, Smhammer L eds Børresen-Dale AL, Fosså SD . A comparison of different modes for the detection of p53 accumulation. A study of bladder cancer Path Res Pract 1997 193: 471–478
Stokke T, DeAngelis P, Smhammer L eds Galteland E, Steen HB, Smeland EB, Delabie J, Holte H . Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell Non-Hodgkin's lymphoma Br J Cancer 2001 85: 1900–1913
Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Bardi A, Campioni D, Minotto C, Agostini P, Milani R, Bullrich F, Negrini M, Croce C, Castoldi G . 13q14 deletion in non-Hodgkin's lymphoma: correlation with clinicopathologic features Haematologica 1999 84: 589–593
Lens D, Matutes E, Catovsky D, Coignet LJA . Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL) Leukemia 2000 14: 427–430
Tanaka K, Arif M, Eguchi M, Guo SX, Hayashi Y, Asaoku H, Kyo T, Dohy H, Kamada N . Frequent allelic loss of the RB, D13S319 and D13S25 locus in myeloid malignancies with deletion/translocation at 13q14 of chromosome 13, but not in lymphoid malignancies Leukemia 1999 13: 1367–1373
Cook WD, McCaw BJ . Accommodating haploinsufficient tumour suppressor genes in Knudsen's model Oncogene 2000 19: 3434–3438
Nakamura M, Sakaki T, Hashimoto H, Nakase H, Ishida E, Shimada K, Konishi N . Frequent alterations of the p14 ARF and p16INK4a genes in primary central nervous system lymphomas Cancer Res 2001 61: 6335–6339
Koduru PRK, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD . Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma Blood 1997 90: 4078–4091
Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VV, Schluger A, Chaganti RS . p53 expression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32) Blood 1995 86: 2892–2899
Møller MB, Ino Y, Gerdes A-M, Skjødt K, Louis DN, Pedersen NT . Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma Leukemia 1999 13: 453–459
Grønbæk K, de Nully Brown P, Møller MB, Nedergaard T, Ralfkiaer E, Møller P, Zeuthen J, Guldberg P . Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma Leukemia 2000 14: 1727–1735
Sherr CJ, Roberts JM . Inhibitors of mammalian G1 cyclin-dependent kinases Genes Dev 1995 9: 1149–1163
Elledge SJ, Harper JW . Cdk inhibitors: on the threshold of checkpoints and development Curr Opin Cell Biol 1994 6: 847–852
Acknowledgements
This study was sponsored by the Norwegian Cancer Society.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Galteland, E., Smedshammer, L., Suo, Z. et al. Proliferation-dependent expression and phosphorylation of pRB in B cell non-Hodgkin's lymphomas: dependence on RB1 copy number. Leukemia 16, 1549–1555 (2002). https://doi.org/10.1038/sj.leu.2402644
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402644
Keywords
This article is cited by
-
Heterogeneous Abnormalities of CCND1 and RB1 in Primary Cutaneous T-Cell Lymphomas Suggesting Impaired Cell Cycle Control in Disease Pathogenesis
Journal of Investigative Dermatology (2006)
-
Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas
Leukemia (2005)